Atherosclerosis
Volume 146, Issue 1 , Pages 141-151 , September 1999

Classical LCAT deficiency resulting from a novel homozygous dinucleotide deletion in exon 4 of the human lecithin: cholesterol acyltransferase gene causing a frameshift and stop codon at residue 144

  • Evelyn M. Teh

      Affiliations

    • The Lipoprotein Research Group, Department of Biochemistry and Molecular Biology, Sir Charles Tupper Medical Building, Dalhousie University, Halifax, NS B3H 4H7, Canada
    • ,
  • Jeffrey W. Chisholm

      Affiliations

    • The Department of Pathology, Wake Forest University School of Medicine, Medical Centre Boulevard, Winston Salem, NC 27157, USA
    • ,
  • Peter J. Dolphin

      Affiliations

    • The Lipoprotein Research Group, Department of Biochemistry and Molecular Biology, Sir Charles Tupper Medical Building, Dalhousie University, Halifax, NS B3H 4H7, Canada
    • Corresponding Author InformationCorresponding author. Tel.: +1-902-4942439; fax: +1-902-4941355
    • ,
  • Yves Pouliquen

      Affiliations

    • Service d’Ophtalmologie, Hotel Dieu, Paris, France
    • ,
  • M. Savoldelli

      Affiliations

    • Service d’Ophtalmologie, Hotel Dieu, Paris, France
    • ,
  • J.L. de Gennes

      Affiliations

    • Service d’Endocrinologie et Métabolisme, Hôpital de la Pitié, Paris, France
    • ,
  • Pascale Benlian

      Affiliations

    • Laboratoire de Commun de Biologie Moléculaire, Hôpital Saint-Antoine, 184 rue du faubourg St.-Antoine, 75012 Paris, France

Received 28 September 1998 ,Revised 17 February 1999 ,Accepted 23 February 1999.

References 

  1. Osuga T, Portman OW. Origin and disappearance of plasma LCAT. Am J Physiol. 1971;220:735–741
  2. Francone OL, Gurakar A, Fielding CJ. Distribution and functions of lecithin: cholesterol acyltransferase and cholesteryl ester transfer protein in plasma lipoproteins. Evidence for a functional unit containing these activities together with apo A-I and D that catalyzes the esterification and transfer of cell derived cholesterol. J Biol Chem. 1989;264:7066–7072
  3. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res. 1995;36:211–228
  4. MacLean J, Wion K, Drayna D, Fielding CJ, Lawn R. Human lecithin: cholesterol acyltransferase gene sequence and sites of expression. Nuc Acid Res. 1986;14:9387–9406
  5. Teisberg P, Gjone E, Olaisen B. Genetics of LCAT (lecithin: cholesterol acyltransferase) deficiency. Ann Hum Genet. 1975;38:327–331
  6. O K, Hill JS, Wang X, McLeod R, Pritchard PH. Lecithin: cholesterol acyltransferase—role of N-linked glycosylation in enzyme function. Biochem J. 1993;294:879–884
  7. Qu SJ, Fan HZ, Blanco-Vaca F, Pownall HJ. Effects of site-directed mutagenesis on the N-glycosylation sites of human lecithin: cholesterol acyltransferase. Biochemistry. 1993;32:8732–8736
  8. Francone OL, Evangelista L, Fielding CJ. Lecithin: cholesterol acyltransferase: effect of mutagenesis at N-linked oligosaccharides attachment sites on acyl acceptor of specificity. Biochim Biophys Acta. 1993;1166:301–304
  9. Schindler PA, Settineri CA, Collet X, Fielding CJ, Burlingame AL. Site-specific detection and structural characterization of the glycosylation of human plasma proteins lecithin: cholesterol acyltransferase and apolipoprotein D using HPLC/electrospray mass spectrometry and sequential glycosidase digestion. Prot Sci. 1995;4:791–803
  10. Norum KR, Gjone E. Familial plasma lecithin: cholesterol acyltransferase deficiency. Scand J Clin Lab Invest. 1967;20:231–243
  11. Norum KR, Gjone E, Glomset JA. Familial lecithin: cholesterol acyltransferase deficiency, including fish-eye disease. In:  Scriver CR,  Beaudet AL,  Sly WS,  Valle D editor. The Metabolic basis of Inherited Disease. New York: McGraw-Hill; 1989;p. 1181–1194
  12. Guérin M, Dolphin PJ, Chapman MJ. Familial lecithin: cholesterol acyltansferase deficiency: further resolution of lipoprotein particle heterogeneity in the low density interval. Atherosclerosis. 1993;104:195–212
  13. Forte T, Nichols AV, Glomset JA, Norum KR. The ultrastructure of plasma lipoproteins in lecithin: cholesterol acyltransferase deficiency. Scand J Clin Lab Invest. 1974;137:121–134
  14. Gotoda T, Yamada N, Murase T, Sakuma M, Murayama N, Shimano H, et al. Differential phenotypic expression by three mutant alleles in familial lecithin: cholesterol acyltransferase deficiency. Lancet. 1991;338:778–781
  15. Funke H, von Eckardstein A, Pritchard PH, Hornby AE, Wiebusch H, Motti C, et al. Genetic and phenotypic heterogeneity in familial lecithin: cholesterol acyltransferase deficiency. Six newly identified defective alleles further contribute to the structural heterogeneity in this disease. J Clin Invest. 1993;91:677–683
  16. Carlson LA, Philipson B. Fish-eye disease: a new familial condition with massive corneal opacities and dyslipoproteinaemia. Lancet. 1979;2:921–924
  17. Carlson LA, Holmquist L. Evidence for deficiency of high density lipoprotein lecithin: cholesterol acyltransferase (α-LCAT) in fish-eye disease. Acta Med Scand. 1985;218:189–196
  18. Carlson LA, Holmquist L. Paradoxical esterification of plasma cholesterol in fish-eye disease. Acta Med Scand. 1985;217:491–499
  19. Carlson LA, Holmquist L. Evidence for the presence in human plasma of lecithin: cholesterol acyltransferase activity (β-LCAT) specifically esterifying free cholesterol of combined pre-β- and β-lipoproteins. Acta Med Scand. 1985;218:197–205
  20. Klein HG, Santamarina-Fojo S, Duverger N, Clerc M, Dumon M-F, Albers JJ, et al. Fish-eye syndrome: a molecular defect in the lecithin: cholesterol acyltransferase (LCAT) gene associated with normal α-LCAT specific activity. J Clin Invest. 1993;92:479–485
  21. Guérin M, Dachet C, Goulinet S, Chevet D, Dolphin PJ, Chapman MJ, et al. Familial lecithin: cholesterol acyltransferase deficiency—molecular analysis of a compound heterozygote: LCAT (Arg147→Trp) and LCAT (Tyr171→stop). Atherosclerosis. 1997;131:85–95
  22. Kuivenhoven JA, Pritchard H, Hill J, Frohlich J, Assmann G, Kastelein J. The molecular pathology of lecithin: cholesterol acyltransferase (LCAT) deficiency syndromes. J Lipid Res. 1997;38:191–205
  23. Gordon D, Rifkind BM. High desity lipoprotein: the clinical implications of recent studies. N Eng J Med. 1989;321:1311–1316
  24. Tall AR. Plasma high density lipoproteins: metabolism and relationship to atherosclerosis. J Clin Invest. 1990;86:379–384
  25. Funke H, von Eckardstein A, Pritchard PH, Albers JJ, Kastelein JJP, Droste C, et al. A molecular defect causing fish-eye disease: an amino acid exchange in lecithin:cholesterol acyltransferase (LCAT) leads to the selective loss of α-LCAT activity. Proc Natl Acad Sci USA. 1991;88:4855–4859
  26. Kuivenhoven JA, van Voorst tot Voorst EJGM, Wiebusch H, Marcovina SM, Funke H, Assmann G, et al. A unique genetic and biochemical presentation of fish-eye disease. J Clin Invest. 1995;96:2783–2791
  27. Kuivenhoven JA, Stalenhoef AFH, Hill JS, Demacker NM, Errami A, Kastelein JJP, et al. Two novel molecular defects in the LCAT gene associated with fish-eye disease. Arterioscler Thromb Vasc Biol. 1996;16:294–303
  28. Winder AF, Owen JS, Vallance DT, Wray R, Lloyd-Jones D, White P. Fish-eye disease at 76 years. 62nd European Atherosclerosis Society Congress 1993;45 (Abstract).
  29. Wiesbusch H, Cullen P, Owen JS, Collins D, Sharp PS, Funke H, et al. Deficiency of lecithin: cholestrerol acyltransferase due to compound heterozygosity of two novel mutations (Gly33Arg and 30 bp ins) in the LCAT gene. Hum Molec Genet. 1995;4:143–145
  30. Cogan DG, Kruth HS, Datilis MB, Martin N. Corneal opacity in LCAT disease. Cornea. 1992;11:595–599
  31. Chapman MJ, Goldstein S, Lagrange S, Lapland PM. A density gradient ultracentrifugal procedure for the isolation of the major classes from human serum. J Lipid Res. 1998;22:339–356
  32. Guérin M, Dolphin PJ, Chapman MJ. A new in vitro method for the simultaneous evaluation of cholesteryl ester exchange and mass transfer between high density lipoprotein and apo-B-containing lipoprotein subspecies. Arteroscler Thromb. 1994;14:199–206
  33. Kuksis A, Myher JJ, Geher K, Hoffman AGD, Breckenridge WC, Jones GJL, et al. Comparative determination of plasma cholesterol and triglycerides by automated gas-liquid chromatographic and autoanalyzer methods. J Chromtogr. 1978;146:393–412
  34. Markwell MA, Haas SM, Bieber LL, Tolbert NE. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem. 1978;87:206–210
  35. Dolphin PJ, Breckenridge WC, Dolphin MA, Tan MH. The lipoproteins of human umbilical cord blood. Apolipoprotein and lipid levels. Atherosclerosis. 1984;51:109–122
  36. Johanson BG. Agarose gel electrophoresis. J Clin Lab Invest (suppl. 29). 1972;124:7–19
  37. Maguire GF, Breckenridge WC. Agarose gel electrophoresis of plasma lipoproteins using durrum cell. Clin Biochem. 1975;8:161–168
  38. Irwin D, O’Looney PA, Quinet E, Vahouny GV. Application of SDS gradient polyacrylamide slab gel electrophoresis to analysis of apolipoprotein mass and radioactivity of rat lipoproteins. Atherosclerosis. 1984;53:163–172
  39. Albers JJ, Chen CH, Lacko AG. Isolation, characterization and assay of lecithin: cholesterol acytransferase. Methods Enzymol. 1986;129:763–782
  40. Chen CH, Albers JJ. Characterization of proteoliposomes containing apoproteins A-I: a new substrate for the measurement of lecithin: cholesterol acyltransferase. J Lipid Res. 1982;23:680–691
  41. Jauhiainen M, Dolphin PJ. Human plasma lecithin: cholesterol acyltransferase: an elucidation of the catalytic mechanism. J Biol Chem. 1986;261:7032–7043
  42. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res. 1988;16:1215
  43. Teh EM, Dolphin PJ, Breckenridge WC, Tan MH. Human plasma CETP deficiency: identification of a novel mutation in exon 9 of the CETP gene in a caucasian subject from North America. J Lipid Res. 1998;39:442–456
  44. Francone OL, Fielding CJ. Structure-function relationships of human lecithin: cholesterol acyltransferase. Site-directed mutagenesis at serine residues 181 and 216. Biochemistry. 1991;30:10074–10077
  45. Peelman F, Vinaimont N, Verhee A, Vanloo B, Verschelde J-L, Labeur C, et al. A proposed architecture for lecithin: cholesterol acyltransferase (LCAT): Identification of the catalytic triad and molecular modeling. Protein Sci. 1998;7:587–599
  46. Bron AJ. Corneal changes in dyslipoproteinaemias. Cornea. 1989;8:135–140
  47. Gjone E, Blomhoff JP, Skarbovik AJ. Possible association between an abnormal low density lipoprotein and nephropathy in lecithin: cholesterol acyltransferase deficiency. Clinica Chim Acta. 1974;54:11–18
  48. Borysiewicz LK, Soutar AK, Evans DJ, Thompson GR, Rees AJ. Renal failure in familial lecithin: cholesterol acyltransferase deficiency. Quarterly J Med. 1982;51:411–426
  49. Murayama N, Asano Y, Hosoda S, Maesawa M, Saito M, Takaku F, et al. Decrease sodium influx and abnormal red cell membrane lipids in a patient with familial plasma lecithin: cholesterol acyltransferase deficiency. Am J Hematol. 1984;16:129–137
  50. Vaisman BL, Klein H-G, Rouis M, Bérard AM, Kindt MR, Talley GD, et al. Overexpression of human lecithin: cholesterol acyltransferase leads to hyperalphalipoproteinemia in transgenic mice. J Biol Chem. 1995;270:12269–12275
  51. Brinton EA, Eisenberg S, Breslow JL. Increased apo A-I and apo A-II fractional catabolic rate in patients with low high density lipoprotein cholesterol levels with or without hypertriglyceridemia. J Clin Invest. 1991;87:536–544
  52. Emmerich J, Verges B, Taureron I, Rader D, Santamarina-Fojo S, Schaefer J, et al. Familial HDL deficiency due to marked hypercatabolism of normal apo A-I. Arterioscler Thromb. 1993;13:1299–1306
  53. Horowitz BS, Goldberg IJ, Merab J, Vanni TM, Ramakrishnan R, Ginsberg HN. Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of HDL cholesterol. J Clin Invest. 1993;91:1743–1752
  54. Norum RA, Lakier JB, Goldstein S, Angel A, Goldberg RB, Block WD, et al. Familial deficiency of apolipoproteins A-I and C-III and precocious coronary artery disease. New Eng J Med. 1982;306:1513–1519
  55. Hoeg JM, Vaisman BL, DemoskyJr SJ, Meyn SM, Talley GD, HoytJr RF, et al. Lecithin: cholesterol acyltransferase overexpression generates hyperalpha-lipoproteinemia and a nonatherogenic lipoprotein pattern in transgenic rabbits. J Biol Chem. 1996;271:4396–4402
  56. Fielding CJ, Frohlich J, Moser K, Fielding PE. Promotion of sterol efflux and net transport by apolipoprotein E in lecithin: cholesterol acyltransferase deficiency. Metabolism. 1982;31:1023–1028
  57. Chambers JAA. Characteristics of Selected proteins. In:  Chambers JAA,  Rickwood D editor. Biochemistry LABFAX. UK: Bios Scientific Publishers, Academic Press; 1993;p. 167

PII: S0021-9150(99)00112-4

Atherosclerosis
Volume 146, Issue 1 , Pages 141-151 , September 1999

Article Tools

* Image Usage & Resolution